Ms. Jennifer M. Kirk

Principal Accounting Officer, Global Controller & Chief Accounting Officer

Mr. Sean  Lennon

Chief Information Officer

Mr. Geoffrey Straub Martha

Chairman & Chief Executive Officer

Mr. Robert John White

Executive Vice President & Pres of Medical Surgical Portfolio

Mr. Robert J. W. ten Hoedt

Executive Vice President & Pres of Global Regions

Mr. Mark  Ploof

Senior Vice President of Global Operations and Bus. Services

Dr. Laura  Mauri M.D., M.Sc.

Senior Vice President and Chief Scientific, Medical & Regulatory Officer

Mr. Ryan  Weispfenning

Vice President of Investor Relations

Ms. Karen L. Parkhill

EVice President, Chief Financial Officer, IT & Enterprise Excellence

Mr. Ivan K. Fong

Executive Vice President, Gen. Counsel & Sec.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

I usually buy stocks with long histories of annual dividend increases when they are trading with historically high yields. I own two stocks that fit this bill recently and I added to them both, with one being more "growthy" than the other.

Here's My Top Growth Stock to Buy Now

Although the biggest and most-established enterprises generally outperform smaller firms during troubled times, this concept doesn't always ring true, meaning that speculators can target beaten-down blue-chip stocks to buy. To be sure, a few advantages exist in targeting this sector over a lesser-capitalized fare.

7 Blue-Chip Stocks to Buy at an All-Time Low

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." --Kiplinger.com/Investing. 67 Aristocrats screened as of March 8, 2023, represented all eleven Morningstar Sectors. Broker estimated top ten net gains ranged 16.32%-32.64% topped by WBA & VFC.

The 4 Dividend Aristocrat Buys For March

Medtronic is seeing a decent rebound to its topline, as the healthcare segment recovers. Management is transforming the company through cost reductions and investments in high growth and synergistic areas.

Medtronic: A Smart Dividend Gem To Buy On The Cheap

Medtronic seems to be a blue-chip company that's committed to increasing its dividend. Its financial position is stable, and its payout ratio is sustainable.

Medtronic: Slow Growth Makes Me Hesitate To Buy

Medtronic Isn’t Out of the Woods Yet

Medtronic Beat Earnings Expectations. The Stock Is Rising.

Medtronic Stock Falls After Medical-Device Maker Posts Lower Earnings

Medtronic Lowers Earnings Guidance, Citing Slower Procedure and Supply Recovery

Medtronic Blood-Pressure Device Curbs Hypertension, but Misses Top Goal in Study

Medtronic Is Doing a Spinoff. The Fallout for Our Stock Pick.  

Medtronic to Spin Off Units

Medtronic's Revenue Fell Short, but Investors Rallied on Guidance

Medtronic Stock Can Gain 20% as Covid Subsides

Medtronic Stock Is Slumping. CEO Geoff Martha Says Covid Issues 'Will Pass.'

Medtronic Stock Is Falling After Sales Miss. It Isn't All Bad News.

Medtronic Stock Slides Because Hypertension Treatment Trial  Wasn't Ended Early

Palo Alto Networks, CrowdStrike, Pinduoduo: What to Watch When the Stock Market Opens Today

Medtronic to Stop Selling Implantable Heart Pump Over Safety Concerns

Elective Surgeries Are Back, Medtronic Says. It's Another Sign of the U.S. Covid Recovery.

Powered by AI

Medtronic plc

78.78